The battle against HIV in sub-Saharan Africa has always been as much about systems and science as about the virus itself. Antiretroviral therapy has turned what was once a death sentence into a ...

Rohit Loomba, M.D., will hold the new endowed chair that was established in honor of the late biotech leader John C. Martin to further liver disease research ...

We had the cure for death from malnutrition, and we took it away.” We speak to surgeon and health policy expert Atul Gawande ...

Topline results were announced from a phase 3 trial evaluating bictegravir 75mg/lenacapavir 50mg (BIC/LEN), an investigational single-tablet regimen for the treatment of HIV-1.

Gilead's Phase 3 ARTISTRY-1 trial shows its single-tablet HIV regimen of bictegravir and lenacapavir matches the efficacy and safety of current therapy.

Avenue 360 Health & Wellness and Omega House hosted Voices for Hope, honoring pioneers of Houston’s HIV response and ...

World AIDS Day Monday, Dec. 1, 2025 | 5–7 p.m. On World AIDS Day, Maui AIDS Foundation (MAF) invites the public to unite in ...

Gilead Sciences (GILD) announced on Thursday that its Phase 3 ARTISTRY-1 trial, which tested its new single-tablet regimen of bictegravir and lenacapavir in adults with HIV, reached the primary ...

Tuberculosis remains the world's leading infectious killer, claiming an estimated 1.23 million lives last year, the UN health organisation said Wednesday (12 November), as it warned that recent gains ...

Franklin County commissioners Rocky Mullen and Clint Didier opposed the increases, while Benton County commissioners Michael ...

Biotech stocks have performed well this year. The SPDR S&P Biotech ETF -- an industry benchmark -- is up 21% this year. Two ...

Gilead Sciences has developed an industry-leading HIV portfolio in recent years with its megablockbuster daily treatment ...